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Abstract
Background: One medication commonly used by HIV-1-infected individuals is the antimicrobial sulphamethoxazole 
(SMX), which is used in the treatment and prophylaxis of pneumocystis pneumonia. However, SMX is responsible 
for a very high incidence of hypersensitivity adverse drug reactions (ADRs) in the HIV-1 population. While the 
pathophysiology of ADRs in general is unknown, sulphamethoxazole-mediated ADRs have been linked to its reactive 
metabolite sulphamethoxazole-hydroxylamine (SMX-HA). Our previous work has shown that increased expression 
of the HIV-1 Tat protein in T cells correlated with increased apoptosis after incubation with SMX-HA. In this study we 
sought to determine the region of the Tat protein responsible for this effect and the mechanism by which Tat contributed 
to SMX-HA mediated apoptosis.
Methods: We established Jurkat T and Cos 7 cell lines that stably expressed full-length Tat (Tat101) and deletion 
mutants (Tat86, Tat72, Tat48 and Tat∆). These cell lines were then incubated with SMX-HA and assayed for cell viability 
and production of reactive oxygen species (ROS). We further used confocal microscopy to assess the intracellular 
distribution of the Tat proteins and to determine if changes in the expression and/or localization of key cytoskeleton 
proteins contributed to Tat-mediated apoptosis after SMX-HA treatment. 
Results: Deletion of regions of Tat that lead to increased cytoplasmic accumulation significantly contributed to 
increased cell death in the presence of SMX-HA. The increased cell death did not require induction of ROS. Quantitative 
analysis also showed that the Tat-expressing cell lines had significantly lower levels of β-actin and α-tubulin present 
both before and after treatment with SMX-HA. Increased cytoplasmic localization of Tat correlated with greater 
disturbances in the distribution of actin filaments. 
Conclusion: The presence of cytoplasmic Tat in T and epithelial cell lines increases their sensitivity to SMX-HA 
induced cell death, an effect mediated by the first 48 amino acids of TAT.
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Introduction
An important consequence of human immunodeficiency virus type 
1 (HIV-1) infection is the decline of the individual’s immune system, 
which allows for vulnerability to opportunistic diseases. The fungus 
Pneumocystis jirovecii takes advantage of this immunodeficiency to 
elicit Pneumocystis pneumonia, a lung infection that is commonly 
treated with the antimicrobial sulphamethoxazole-trimethoprim 
(SMX-TMP), more commonly known as cotrimoxazole. This standard 
combination of two antimicrobials is also used to treat urinary tract 
infections in the HIV-1-negative population. The SMX moiety of the 
drug has been associated with risk of adverse drug reactions (ADRs) 
at an incidence of 2-5% [1]. However, the incidence of SMX ADRs 
increases to 50% or more in HIV-1 infected individuals as progression 
to AIDS occurs [1]. ADRs are conventionally defined as a response to 
a drug that is noxious and unintended, occurring at doses normally 
used for prophylaxis or treatment [2]. One of the most serious types 
of ADRs are the hypersensitivity ADRs which usually present as a 
delayed reaction characterized by the onset of fever and a rash that can 
often develop into serious skin conditions such as Stevens-Johnson 
syndrome or toxic epidermal necrolysis, both of which can be fatal [2]. 
Clinical manifestations of hypersensitivity ADRs are highly diverse 
and often involve numerous organs such as the liver and kidneys 
[2]. These symptoms are similar in HIV-1-infected and uninfected 
patients, however severe reactions such as Stevens-Johnson syndrome 
or toxic epidermal necrolysis are much more common in HIV-1-
infected individuals [3]. The risk of an SMX-induced ADR significantly 
increases as HIV-1 infection progresses to AIDS, specifically when 
HIV-1 infection is uncontrolled which suggests that virus infection 
can adversely modify the manner in which host-drug interactions take 
place.  
The hapten hypothesis has been advanced as being key to the 
pathogenesis of drug hypersensitivity in general and those stimulated 
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by SMX in particular. This hypothesis postulates that bioactivation and 
haptenation of the drug to a cellular protein or proteins is critical to 
the initiation of an immune response. Sulphamethoxazole undergoes 
bioactivation by the cytochrome P450 enzyme CYP2C9 to its 
hydroxylamine metabolite that is then auto-oxidized to nitroso-SMX, 
both of which are known to be toxic to cells in vitro [4,5]. Indeed, this 
toxicity was the basis for an in vitro model of hypersensitivity ADRs 
as peripheral blood lymphocytes from patients with a history of 
hypersensitivity ADRs showed significantly increased toxicity across a 
concentration range of SMX-HA compared to those from controls and 
patients with a history of non-hypersensitivity reactions [6]. A similar 
finding was reported in HIV-1-positive patients where SMX-HA 
cytotoxicity was greater in patients known to exhibit hypersensitivity 
ADRs [7] and, as we previously demonstrated, also correlated with 
HIV-1 infection in established T cell lines and with the expression of 
recombinant HIV-1 Tat (Transactivator of transcription) protein in T 
cell lines [4,8]. 
Tat is a small, non-structural transcriptional regulator essential for 
the efficient replication of HIV-1. Tat binds to the TAR (Tat activation 
region) sequence, a stable RNA hairpin that forms at the end of all 
nascent viral transcripts, which leads to the recruitment and activation 
of cellular factors that potentiate RNA polymerase II to synthesize full-
length HIV-1 transcripts [9]. The coding sequences of the Tat gene are 
located on two exons and the resultant protein has a molecular weight 
of 14-16 kDa. Tat is made up of 101 amino acids with residues 1-72 
encoded by the first exon and residues 73-101 encoded by the second 
exon. The 101 amino acid form of Tat is what is found predominantly 
in clinical isolates from all HIV-1 subtypes except subtype D, which 
has a non-synonymous single nucleotide polymorphism creating a stop 
codon in the second exon and an 86 amino acid protein [10]. Though 
a few laboratory strains exist that express an 86 amino acid form of 
Tat, this version is thought to represent an artificially truncated protein 
[11,12]. 
The full-length Tat protein can be divided into six domains: the 
N-terminal domain (aa 1-21), cysteine-rich domain (aa 22-37), core 
domain (aa 38-47), basic domain (aa 48-60), glutamine-rich domain 
(aa 61-72) and the C-terminal domain (aa 73-101) [10,13]. The first 
three domains (aa 1-48) together contain the minimum activation 
domain of the protein which mediates its interactions with cellular 
transcription machinery [9,14,15]. The basic domain in conjunction 
with the glutamine-rich domain confers the Tat activation region (TAR) 
RNA binding properties to Tat. Therefore the product of the first exon 
(aa 1-72), representing the activation domains and the TAR-binding 
region, is all that is required for functional HIV-1 transactivating 
activity. The basic domain is also known as the protein transduction 
domain (PTD) and contains a nuclear localization sequence (NLS). The 
PTD confers on Tat the ability to exit HIV-1 infected cells and enter 
uninfected bystander cells. This form of Tat is known as extracellular Tat 
and is able to modulate gene expression of a number of cellular genes 
in both infected and uninfected cells [9,16]. Ultimately, extracellular 
Tat is thought to facilitate the spread and pathogenesis of HIV-1 by 
contributing to the apoptosis and eventual depletion of the CD4+ T cell 
subset [17-20]. 
We have previously demonstrated SMX-HA induced cell death via 
apoptosis in a cultured T cell line expressing the first exon of the HIV-
1 Tat protein [21]. Here we determine the mechanism by which SMX 
-HA enhances Tat’s ability to promote apoptosis using the full-length 
form of Tat. One mechanism by which Tat has been demonstrated to 
enhance apoptosis is by the production of reactive oxygen species (ROS) 
[12], therefore we looked at ROS production in the Tat-expressing cell 
lines in the absence and presence of SMX-HA. Another pro-apoptotic 
mechanism utilized by extracellular Tat involves its specific interaction 
with the αβ-tubulin dimer and polymerized microtubules of the 
cytoskeleton [22]. This Tat-tubulin interaction is dependent on residues 
36-39 which is a four-amino-acid subdomain that overlaps with the 
core domain [22]. Tat has also been shown to affect the rearrangement 
of the actin cytoskeleton [23]. In the current study we determined 
which region of the Tat protein facilitated the cellular toxicity to SMX-
HA and if there was any correlation to the expression of cytoskeletal 
proteins. We also determined if changes in the expression and/or 
localization of key cytoskeleton proteins enhances apoptosis of Jurkat 
T cells expressing intracellular Tat, when the protein is synthesized 
inside the cell as during an HIV-1 infection. We provide new evidence 
that in the presence of both HIV-1 Tat and SMX-HA, a T cell is more 
susceptible to apoptotic cell death and may be the first step in a cascade 
of events that leads to the increase in SMX-associated ADR in HIV-1 
infected persons.  
Materials and Methods
Cell lines
The human T lymphocyte cell line Jurkat E6.1 (ATCC TIB-152), 
was obtained from the American Type Culture Collection (ATCC). The 
cell line was maintained in Complete RPMI 1640 medium (Invitrogen) 
supplemented with 1% L-glutamine, 10% fetal calf serum and 100 
units/ml of penicillin and streptomycin. The Cos-7 cell line (ATCC 
CRL 1651), a monkey kidney fibroblast-like cell line was maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal 
calf serum and 100 units/ml of penicillin and streptomycin.
Construction of plasmids and cell lines: The Tat gene was PCR-
amplified from the plasmid pSVTat. This plasmid encodes the full-
length Tat gene and was a kind gift from Dr. KT Jeang at the Laboratory 
of Molecular Microbiology, the Molecular Virology Section, NIAID, 
NIH. The full-length Tat gene (Tat101), with or without stop codons, 
and Tat deletion mutants (Tat86, Tat72, Tat48 and Tat∆(49-59)) were 
cloned into the plasmid pEGFP-N1 (Clontech Inc.), resulting in 
Tat101, Tat101GFP, Tat86GFP, Tat72GFP, Tat48GFP and Tat∆GFP 
fusion gene, respectively. The fusion genes were then subcloned into 
pBIG2i as previously described [21]. The results were the following 
plasmid constructs; pBIG Tat101, pBIG Tat101GFP, pBIG Tat86GFP, 
pBIG Tat72GFP, pBIG Tat48GFP and pBIG Tat∆GFP. As a control, the 
GFP gene from pEGFP-N1 was also cloned into pBIG2i to create pBIG 
GFP. The pBIG Tat constructs or pBIG GFP were transfected into Jurkat 
E6.1 T cells by nucleofection (Lonza, Amaxa Nucleofector) according 
to the manufacturer’s instructions and stable cell lines were generated 
as previously described [21]. Cos-7 cells were also transfected with 
the pBIG TatGFP constructs for confocal microscopy studies. The 
expression of the fusion proteins or GFP in either cell type was induced 
by incubating the transfected cells with doxycycline (Sigma, Canada).
Source of SMX-HA
SMX-HA was synthesized by Katarina Sapeta in the laboratory of 
Dr. Michael A. Kerr at the Department of Chemistry, the University of 
Western Ontario.
Dose response and time course of doxycycline induction: The 
concentration of doxycycline required to induce expression of the 
TatGFP fusion proteins was determined in dose-response experiments 
where cells from the different cell lines were incubated with 0-1000 
ng/ml of doxycycline for 40 h and then the cells were analyzed on a 
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FACS (fluorescence-activated cell sorting) Calibur instrument (Becton 
Dickinson). Time course experiments were conducted by incubating 
cells with 0-1000 ng/ml of doxycycline for 72 h, with aliquots taken 
at 12 h intervals and analyzed by flow cytometry on a FACS Calibur. 
In both the dose response and time course experiments at least 
10,000-gated events were measured for each sample. Flow cytometry 
data were analyzed and the percentage of GFP+ cells determined using 
the FlowJo program (Tree Star, Inc.).
Real time PCR analyses of Tat/GAPDH mRNA levels
To compare the level of Tat mRNA present in the stable cell lines 
with that in HIV-1-infected cells, cells from each of the stable pBIG 
TatGFP cell lines were induced by treatment with 0, 200, 400, 600, 800 
and 1000 ng/ml doxycycline for 40h and total RNA was extracted using 
the RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. 
RNA was also isolated from HIV-1IIIB-infected Jurkat T cells. Total 
RNA (10 μg) was reverse transcribed using the High Capacity cDNA 
Archive Kit (Applied Biosystems) according to the manufacturer’s 
instructions. Control real time-PCR reactions were performed in 
the absence of cDNA templates and GAPDH was used as a control 
housekeeping gene. Real time-PCR analysis was performed using the 
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) 
with TaqMan assays. Relative expression levels were determined by the 
comparative cycle threshold method [24].
Western blot analysis
To characterize the expression of the TatGFP fusion proteins in the 
Jurkat T cell lines, cells were differentially induced with doxycycline for 
40 h, washed twice in PBS then solubilized with RIPA buffer containing 
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium 
deoxycholate, 0.1% SDS, 1 mM EDTA and complete mini protease 
inhibitor cocktail (Roche). The lysates were sonicated for 2 × 20 sec 
then centrifuged at 13,000 rpm for 15 min at 4°C. The supernatants 
were collected and the protein concentrations were determined using 
the DC Protein Assay (BioRad) and bovine serum albumin (BSA) 
as standards. The proteins were resolved on a 15% SDS-PAGE gel, 
transferred to a PVDF (polyvinylidene difluoride) membrane and 
probed for Tat (Advanced Biotechnologies Inc.). Bound antibody was 
detected using goat anti-mouse horseradish peroxidase-conjugated 
secondary antibody and enhanced chemiluminescence (Amersham). 
GAPDH (Sigma) was used as a control for protein loading.
Tat-expressing Cos-7 cells were seeded in 6-well plates at a density 
of 2 x 105 cells/well and induced with 0, 200 or 2000 ng/ml doxycycline 
for 40 h. The cells were washed with PBS and treated with 0.05% 
DMSO (vehicle) or 200 µM SMX-HA diluted in HEPES buffer for 2h 
at 37°C. This was followed by another 2 h incubation with media at 
37°C after which the cells were collected and protein extracted as stated 
above. 1 µg of BSA was added to each 20 µg sample of protein that 
was then resolved on 12% SDS-PAGE. The proteins were transferred 
onto PVDF membranes and probed with anti-α-tubulin (Sigma 
Aldrich), anti-β-actin (Sigma Aldrich) or anti-BSA (Life Technologies) 
antibodies. Densitometric analysis was performed with FlouChem Q 
(AlphaInnotech) using BSA as a loading control.
MTT cell viability assay
Drug toxicity was measured using the MTT (3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; Sigma-
Aldrich) cell proliferation assay. Cell proliferation was quantified by 
colorimetric conversion of MTT [25]. Briefly, Jurkat pBIG TatGFP 
cells were differentially induced with doxycycline for 40 h, washed 
twice with PBS then 7.5 x 104 cells/well were seeded in 96-well plates 
and incubated in HEPES buffer with 200 µM SMX (Sigma-Aldrich) or 
0-400 µM of SMX-HA for 2 h. After the drug was removed, the cells 
were resuspended in media and incubated at 37°C for 18 h. Next, 1 
mg/ml MTT was added to the wells and incubated at 37°C for another 
4 h. The reaction product that precipitated was solubilized overnight 
at room temperature by the addition of the stop solution (50% N, 
N-dimethylformamide/ 20% SDS) to the wells. The following morning 
the absorbance in the wells was determined by an ELISA plate reader at 
590 nm and equated to the percentage of viable cells with the help of a 
standard curve. This assay was performed on three separate occasions 
for each cell line.
Detection of reactive oxygen species
Following the 40 h doxycycline induction, the cells were washed 
twice in PBS and resuspended in HBSS (Hank’s buffered saline solution) 
at a concentration of 1 × 106 cells/ml. Cell suspension (100 µl) was placed 
in wells of a 96-well plate, the plate centrifuged at 1500 rpm for 5 min 
and the supernatant decanted. To each well 100 µl of 20 µM DCFH-DA 
(2’, 7’-dichlorfluorescein-diacetate, Sigma) in HBSS was added and the 
plate was incubated at 37°C for 1h after which the plate was centrifuged 
at 1500 rpm for 5 min and the supernatant decanted. The wells were 
filled with 100 µl HBSS and background fluorescence read at 485 nm 
excitation and 527 nm emission. SMX-HA was added to the wells in 
quadruplicates and the plate is incubated at 37°C with fluorescence 
readings at 30 min intervals for 2 h. This assay was performed on three 
separate occasions for each cell line.
Confocal microscopy
Mitochondrial imaging - Cos 7 pBIG TatGFP cells were incubated 
with 500 ng/ml of doxycycline for 40h, incubated with 6 µM MitoTracker 
Far Red (Invitrogen) and 10 µM Hoechst 33258 (Sigma-Aldrich) for 20 
min at 37°C. 
Cytoskeletal imaging - Cos 7 cells were incubated with 500 ng/
ml of doxycycline for 40 h, treated with 200 µM SMX-HA for 2 h at 
37°C and then incubated with media only for an additional 2 h, again 
at 37°C. The cells were stained with 10 µM Hoechst 33258 for 15 min 
at 37°C, then washed with PBS, fixed with 1% paraformaldehyde (PFA) 
for 10 min at room temperature and permeabilized with cold acetone 
at -20°C for 4 min. The rest of the procedure was carried out at room 
temperature. Cells were washed thrice with PBS, blocked with 1% BSA 
for 30 min and then incubated with mouse monoclonal anti-α-tubulin 
(Sigma Aldrich) for 30 min. After three more washes with PBS the cells 
were incubated with Alexa Flour 633 goat anti-mouse IgG (Molecular 
Probes) for 30 min and then Alexa Flour 546 phalloidin (Molecular 
Probes) was added for 20 min.
The images were taken with a Zeiss LSM 510 META confocal 
microscope and processed using Image-Pro 5.0 (Media Cybernetics) 
and Adobe Photoshop CS2 (Adobe Systems, Inc.). The actin proteins 
were pseudocoloured.
Statistics
MTT cell viability data were analyzed in GraphPad Prism version 
5 (GraphPad Software Inc., San Diego, CA). A two-way ANOVA with 
Bonferonni’s post hoc procedure was used to compare mean differences 
between groups for different concentration levels. The LC50 values were 
calculated using GraphPad Prism 5, where the X values (concentration 
of SMX-HA) were log-transformed and the Y values (% cell viability) 
were normalized to define 0% and 100% as the smallest and highest 
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values, respectively. This was followed by sigmoidal dose-response 
(variable slope) curve-fit. GraphPad Prism (GraphPad Software Inc., 
San Diego, CA) was also used to calculate mean and standard error for 
the real time-PCR data as well as the western blot densitometer data.
Results
TatGFP constructs
As we have previously established that T cells undergo apoptosis 
when expressing HIV-1 Tat and exposed to SMX-HA (8, 21), we wanted 
to understand the mechanism(s) behind the increased sensitivity 
to SMX-HA including what regions or properties of Tat contributed 
to this process. We began by constructing and expressing full length 
Tat and Tat deletion mutants (Figure 1) fused to EGFP as previously 
described [21]. Briefly, the full-length HIV-1 Tat protein (Tat101) 
was PCR amplified and subcloned onto the N-terminal end of an 
EGFP plasmid to create the fusion protein Tat101GFP. Five deletion 
mutants of the Tat protein were similarly generated to produce the Tat-
EGFP fusion protein constructs Tat48GFP, Tat72GFP, Tat86GFP and 
Tat∆GFP, which expressed the full-length protein without the NLS/
PTD. The fusion constructs were inserted into a doxycycline-inducible 
vector pBIG2i and subsequently used to establish stably transfected 
Jurkat E6.1 T and Cos-7 cell lines derived from single cell clones.
Characterization of the TatGFP-expressing cell lines
Each stably transfected Jurkat T cell line was characterized by 
western blotting to determine if the Tat portion of the correct fusion 
proteins was present. To this end, cells from each of the lines were 
incubated for 40 h with 0-1000 ng/ml Dox then lysed and protein 
extracted. The use of specific anti-Tat antibodies showed the induction 
of the TatGFP fusion protein of the correct size in each of the cell lines 
at different concentrations of doxycycline (Figure 1). An analogous 
experiment was carried out with stably transfected Cos7 cells that 
were incubated with 0-2000ng/ml Dox before protein extraction. The 
increasing expression of the TatGFP proteins was observed in these cell 
lines, similar to that seen in the Jurkat cell lines (data not shown).
Time course experiments were carried out to determine the 
induction profile of each Tat fusion protein expression at different 
doxycycline concentrations as well as the point at which the cell lines 
were maximally induced for the expression of their various TatGFP 
fusion proteins. The different cell lines were incubated with 0-1000 ng/
ml of doxycycline and aliquots taken at various time points and analyzed 
by flow cytometry. The cell lines expressing Tat and its deletion mutants 
demonstrated very similar kinetics of GFP induction. In all the cell 
lines, increasing the concentration of doxycycline produced an increase 
in the percentages of GFP-expressing cells at every time point (Figure 
2). The exact percentage of GFP-expressing cells at each concentration 
of doxycycline tested differed slightly for each of the cell lines. However, 
the maximal level of induction at 500-1000 ng/ml doxycycline was able 
to induce at least 85% of the cells to express GFP in all tested cell lines. 
In addition, GFP expression generally began to plateau at the 36 h time 
point and was maintained for at least the 72 h period, the longest time 
tested in these experiments. In four of the five cell lines (Tat101GFP, 
Tat72GFP, Tat86GFP and Tat∆GFP), there were a negligible percentage 
of cells exhibiting GFP fluorescence in the absence of doxycycline (0ng/
ml). The exception was the Tat48GFP cell line, where at the initial 
time point approximately 6% of cells had detectable levels of GFP 
fluorescence in the absence of doxycycline (0ng/ml) (Figure 2). 
In an effort to compare the level of Tat expression in the engineered 
cell lines to that in chronically HIV-1-infected cells, quantitative real 
Figure 1: Expression of Tat constructs after differential induction. The left 
panel shows the functional domains of the various Tat constructs and on 
the right is the expression of the respective proteins from the constructs 
after differential induction by doxycycline. Cells from the (A) Tat101GFP, (B) 
Tat86GFP, (C) Tat72GFP, (D) Tat48GFP and (E) Tat∆GFP lines were treated 
with different concentrations of doxycycline (0-1000ng/ml) for 40 h and then 
the cells were lysed and protein extracted. The proteins were analyzed on 
SDS-PAGE and membranes blotted with anti-Tat antibodies. GAPDH was 
used as a loading control. Data are representative of two independent 
experiments.
Figure 2: Time course of TatGFP expression following differential 
doxycycline induction. Cells from (A) Tat101GFP, (B) Tat86GFP, (C) 
Tat72GFP, (D) Tat48GFP, and (E) Tat∆GFP lines were treated with 
various concentrations of doxycycline then incubated for 72 h. Aliquots 
of cells were analyzed by flow cytometry (Calibur) for GFP expression 
at six different time points. Data are mean of three independent 
experiments.
Citation: Adeyanju K, Dekaban GA, Rieder MJ (2016) Cytoplasmic Distribution of HIV-1 Tat Sensitizes Jurkat T cells to Sulphamethoxazole-
Hydroxylamine Induced Toxicity. HIV Curr Res 1: 105. 
Page  5  of 12
Volume 1 • Issue 1 • 1000105
HIV Curr Res
ISSN: HICR, an open access journal
time PCR was performed. This was necessary as the Tat protein in 
the HIV-1-infected Jurkat T cells (Jurkat-HIV-1) was undetectable 
via western blots. Using primers specific for spliced Tat mRNA, 
quantitative PCR detected Tat mRNA in all the cell lines as well as in the 
Jurkat-HIV-1 cells. The results showed that Tat mRNA expression in 
the TatGFP cell lines increased as the concentration of doxycycline was 
increased from 0-1000 ng/ml. Furthermore, the amount of Tat mRNA 
detected in the Jurkat-HIV-1 cells was comparable to that seen in the 
TatGFP cell lines though the concentration of doxycycline needed to 
reach equivalent levels of Tat mRNA differed for each cell line (Figure 
3). The concentrations of Dox that gave the equivalent concentration 
of Tat mRNA in HIV-1 infected cells was used in all subsequent 
experiments unless indicated otherwise in order that the level of Tat 
was physiologically relevant to that of an HIV-1 infected T cell.
Intracellular localization of TatGFP constructs
Studies have previously shown that fusion proteins utilizing the PTD 
of the Tat protein are transported into the mitochondria from outside 
the cell [26]. To determine if Tat synthesized in the cell (intracellular 
Tat) enters the mitochondria, confocal microscopy was used to visualize 
the intracellular localization of the different TatGFP proteins following 
transfection of Cos 7 cells. These experiments were carried out in Cos 
7 cells as they are more conducive to this type of image analysis than 
the smaller, round Jurkat T cells that have minimal cytoplasm. The cells 
were induced for Tat expression then stained for mitochondria and for 
nuclear DNA. The confocal images showed that the GFP fluorescence 
of the Tat101GFP and Tat72GFP proteins are co-localized with the 
Hoechst stain in the nucleus (Figure 4), while the mitotracker-stained 
mitochondria were evenly distributed throughout the cytoplasm 
(Figure 4(A-C)). The same pattern was seen with Tat86GFP (data not 
shown). In contrast, both the Tat∆GFP and Tat48GFP proteins showed 
GFP fluorescence both in the nucleus and cytoplasm of the cells. This 
dispersal of GFP fluorescence was also seen in the corresponding Tat-
expressing Jurkat T cell lines (Supplemental Figure 1). The distribution 
of the mitochondria in the cytoplasm of the Tat48GFP-expressing cell 
was similar to that of the other TatGFP fusion proteins (Tat101GFP, 
Tat86GFP and Tat72GFP, Figure 4D) while mitochondrial aggregation 
was observed around the nucleus in cells expressing Tat∆GFP (Figure 
4E). The non-punctate/diffuse nature of the GFP fluorescence in the 
Tat∆GFP and Tat48GFP-expressing cells suggests there was no co-
localization between GFP and the relatively structured organization 
of mitochondria in these cells (Figures 4D and E). One method to 
quantify protein co-localization within subcellular structures relies on 
their fluorescent intensity line profiles [27]. An examination of the line 
profiles for the images from the Tat∆GFP and Tat48GFP-expressing 
cells showed there was no observable colocalization of GFP fluorescence 
with mitotracker-stained mitochondria (Supplemental Figure 2).
Cell Viability of Tat-expressing cell lines after treatment with 
SMX-HA
Earlier studies have consistently demonstrated concentration-
dependent toxicity when SMX-HA is incubated with cells from patients 
with a history of hypersensitivity ADRs to SMX compared to the cells 
of controls [6]. Our studies have also shown that this effect on viability 
is amplified in the presence of the Tat protein and is also influenced 
by the amount of Tat protein in the cell [8]. The Tat-expressing cell 
lines were used to determine the region or domain of the protein that 
is involved in enhancing toxicity. These cell lines were evaluated using 
the MTT cell viability assay and were carried out using un-induced cells 
(controls) and cells exposed to different concentrations of doxycycline 
Figure 3: Quantification of Tat mRNA in the cell lines (A) Tat101, (B) 
Tat101GFP and (C) data from the other cell lines. Cells were treated 
with doxycycline for 40 h then RNA was extracted. Total RNA (10µg) was 
reverse transcribed and used to generate a standard curve with GAPDH 
serving as the housekeeping gene. Tat mRNA was detected using a Tat-
specific primer. Data are mean of three independent experiments.
Figure 4: Confocal images showing localization of the Tat constructs 
and mitochondrial distribution. Cells from (A) Cos, (B) Tat101GFP, (C) 
Tat72GFP, (D) Tat48GFP, and (E) Tat∆GFP lines were treated with 
doxycycline for 40 h, stained with Mitotracker Red and Hoechst 33258 
stain, and then analyzed under a Zeiss LSM 510 META confocal 
microscope. The scale bar represents 5 µm.
to induce different amounts of Tat, including that needed to reach the 
Tat levels of HIV-1 infected Jurkat cells. 
As previously demonstrated, neither the pro-drug SMX nor 
the vehicle DMS0 (0 µM SMX-HA) had any significant effect on the 
cellular viability of Jurkat T cells as the viability of each of the different 
cell lines remained above 95% for the duration of the MTT assay (data 
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Figure 5: The effect of Tat constructs on cell toxicity in the presence of SMX-HA. Tat expression was induced for 40 h from (A) Tat101, (B) Tat101GFP, (C) 
Tat86GFP, (D) Tat72GFP, (E) Tat48GFP or (F) Tat∆GFP lines by treatment with various concentrations of doxycycline (0-1000ng/ml) then incubated with 
0-400µM SMX-HA for 2 h after which the drug was replaced with media and the cells incubated at 37°C. The next day the cells were incubated with 5mg/ml 
of MTT again at 37°C for a period of 4 h. The percent cell viability was then determined the following day via a plate reader at 590 nm. Data from each cell 
line are mean of three independent experiments, with the exception of Jurkat E6.1. The results from the Jurkat E6.1 cells in each panel are the average of 
25 different MTT experiments carried out in conjunction with different Tat-expressing cell lines over a course of several months. *P<0.001 vs. Jurkat E6.1.
not shown). While the difference in cell viability between the Tat101-
expressing and Jurkat E6.1 cells was significant at 400 µM SMX-HA, 
there was no significant difference between the differentially induced 
Tat101 cells at this concentration (Figure 5A). Cell toxicity of the Jurkat 
E6.1 parental cells was significantly different from Tat101GFP cells 
induced with 100 ng/ml Dox at 200 µM and 400 µM SMX-HA (Figure 
5B). While cells induced with 500ng/ml doxycycline followed the 
general trend of decreased cell viability with increasing concentrations 
of SMX-HA, these cells did not demonstrate changes in viability that 
were significantly different from doxycycline untreated cells (Figure 5B, 
0 ng/ml Dox). 
The Tat86GFP cell line showed a slight increase in the proliferation 
of cells induced with 200 ng/ml Dox and treated with 50-100 µM SMX-
HA in comparison to the other cell populations (Figure 5C) with a 
significant increase in cell proliferation compared to Jurkat E6.1 cells 
at 100µM SMX-HA. As well, there was a significant decrease between 
the 200 ng/ml Dox and the 800 ng/ml Dox cell populations at 100 µM 
SMX-HA (Figure 5C). There was also a significant decrease in viability 
of the Tat86GFP cells compared to Jurkat E6.1 cells at 400 µM SMX-
HA. The Tat72GFP cell line did not show a significant decrease in cell 
viability until 400 µM SMX-HA (Figure 5D). However, the differential 
induction of Tat72GFP had no significant effect on cell viability at any 
concentration of SMX-HA. 
In contrast, the Tat48GFP and Tat∆GFP-expressing cell lines 
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demonstrated significant decreases in viability compared to Jurkat E6.1 
cells at 50 µM SMX-HA, a lower treatment dose than seen with any of 
the cell lines described above (Fig 5E and 5F). At 100 µM SMX-HA, 
the viability of the 0 ng/ml population had dropped to approximately 
40%, significantly lower than cell viabilities of 90% and above of the 
cell lines expressing Tat101, Tat101GFP, Tat86GF or Tat72GFP. Cell 
viability continued to decrease at the higher concentration of SMX-HA, 
but there was no significant difference in the differentially induced cells. 
Comparing the LC50 (lethal concentration, 50%) of each of the 
cell lines demonstrated that both the Tat48GFP and Tat∆GFP cell 
lines were particularly sensitive to SMX-HA. As shown in Table 1, the 
LC50 values for the Jurkat E6.1, Tat101, Tat101GFP, Tat86GFP and 
Tat72GFP cell lines were in the concentration range of 200-300 µM 
SMX-HA while that of Tat48GFP and Tat∆GFP was 2-fold to six-fold 
lower at 67-106 µM and 52-59 µM SMX-HA respectively. In an effort to 
determine if this phenomenon was clone-specific, the pBIG Tat48GFP 
and pBIG Tat∆GFP DNA was used to transfect Jurkat E6.1 cells and 
the pool of stably selected transfectants rather than single cell clones 
was used in the MTT assay. The result was an LC50 of 137-160 µM 
and 138-149 µM respectively. While in both cases these LC50 values 
were higher than the LC50 found in the assay using specific clones, they 
were still significantly lower than the other cell lines, indicating that 
the Tat48GFP and Tat∆GFP cell lines were more sensitive to SMX-HA-
induced toxicity.
Generation of ROS by Tat-expressing cell lines  
HIV-1 Tat has been reported to induce the formation of reactive 
oxygen species (ROS) that leads to apoptosis in T cells [12]. To 
determine if ROS contributed to cell death observed in the MTT assays, 
the pro-oxidant effects of the Tat protein and its deletion mutants 
were evaluated. Cells from the various cell lines were induced with 
doxycycline and then incubated in the presence of SMX or SMX-HA 
and DCFH, a cell permeable dye whose oxidized form fluoresces in the 
presence of ROS. Incubation with SMX generated ROS in negligible 
amounts similar to the fluorescence seen when the cells were incubated 
with the vehicle DMSO. Significant production of ROS was only evident 
upon the addition of SMX-HA to each of the cell lines (Figure 6) 
resulting in a 3- and 8-fold increase in ROS produced. In the Tat101 and 
Tat101GFP-expressing cell lines, a general trend was observed whereby 
increases in the doxycycline concentration lead to small, but significant 
increases in ROS production (Figures 6A and 6B). However, the 
doxycycline-induced expression of Tat86GFP (Figure 6C), Tat72GFP 
(Figure 6D), Tat48GFP (Figure 6E) and Tat∆GFP (Figure 6F) did not 
significantly increase ROS production. In contrast, there was a marked 
difference in the amount of ROS generated by the Tat101, Tat101GFP 
and Tat86GFP cell lines compared to the other cell lines. Indeed the 
other cell lines produced far less ROS (~40-50% less) in the presence 
of SMX-HA, indicating that the pro-oxidant effect of Tat depends on 
the presence of its C-terminal domain. Additionally, this property of 
Tat seemed to only be effective when the protein was localized to the 
nucleus, as the ROS generated by the Tat∆GFP-expressing cell line in 
the presence of SMX-HA did not reach the magnitude observed in the 
Tat101GFP cell line.
Expression and intracellular distribution of actin and tubulin
The discrepancy between the Tat-expressing cell lines with 
significant levels of cell death after SMX-HA treatment (Figures 5E and 
5F; Tat48GFP and Tat∆GFP) and those that produced considerable 
amounts of ROS in the presence of SMX-HA (Fig 6A and 6B; Tat101 
and Tat101GFP) suggested that oxidative stress was not the primary 
mode of cell death. Therefore, we investigated other mechanisms 
of Tat-induced cell death. Several studies have illustrated the ability 
of extracellular Tat to affect the cytoskeleton, mainly by altering 
cytoskeletal dynamics. Extracellular Tat can cause actin cytoskeletal 
rearrangements and, at high concentrations, cytoskeletal disassembly 
and collapse [23-28]. Extracellular HIV-1 Tat has also been shown to 
bind tubulin, enhance microtubule polymerization and induce apoptosis 
by causing the formation of abnormally stable microtubules [22,29,30]. 
The contribution of intracellular Tat to changes in the expression and 
function of cytoskeletal proteins remains undocumented. To determine 
if this is occurring in the context of SMX-HA treatment, we first induced 
TatGFP expression with a low (200 ng/ml Dox) and a high (2000 ng/
ml Dox) concentration of doxycycline in Cos 7 cells stably-expressing 
the different deletion mutants of Tat. We then looked at changes in the 
expression of the cytoskeletal proteins β-actin and α-tubulin before 
and after treatment with SMX-HA. Quantitative analysis showed 
that the cell line expressing Tat101GFP had significantly lower levels 
of β-actin and α-tubulin both before and after treatment with SMX-
HA, suggesting the full-length Tat protein was able to down-regulate 
these proteins. The expression levels of β-actin and α-tubulin in cells 
expressing TatΔGFP, Tat48GFP, and Tat72GFP followed in ascending 
order (Figure 7).
Confocal imaging of untransfected and Tat-expressing Cos 7 cells 
was also carried out to visualize the intracellular distribution of actin 
and tubulin proteins after SMX-HA treatment (Figure 8). Of the stably-
expressing TatGFP cell lines examined, those expressing Tat101GFP 
and Tat72GFP were able to broadly retain the organization of their 
actin filaments which formed straight lines that traversed the cell. 
Cells expressing Tat48GFP exhibited the most stress after SMX-HA 
treatment with the cells generally exhibiting a complete disorganization 
of the actin filaments that pooled at different parts of the cell, leading to 
cells with a shrunken appearance. There were no straight lines of actin 
filaments in the Tat∆GFP-expressing cells, but neither was there the 
aggregation of actin as seen in cells expressing Tat48GFP. Consistent 
with Tat stabilizing tubulin filaments, the intracellular distribution 
of α-Tubulin was not affected as filaments were seen throughout the 
cytoplasm of all cells. The images also did not show any discernable 
interaction between the TatGFP proteins and α-tubulin. These 
observations were true not only for the nuclear-localized Tat101GFP 
and Tat72GFP proteins, but also the Tat48GFP and Tat∆GFP proteins 
both of which exhibit a significant cytoplasmic distribution. Though 
there was an increased distribution of β-actin around the edges of the 
TatGFP-expressing Jurkat T cells, there was no discernable pattern or 
structure to the distribution of either β-actin or α-Tubulin within the 
cells, perhaps due to the limited area of the cytoplasm (Supplemental 
Figure 3).
Discussion
Adverse drug reactions occur at a higher frequency in HIV-1-
positive patients than in the general population [1]. These reactions 
occur in a number of therapeutic classes, including antiretroviral drugs 
and the antibiotics used to prevent or treat opportunistic infections. 
One of the most common drugs responsible for adverse effects in HIV-
1-infected individuals is the antimicrobial agent SMX. ADRs to SMX in 
patients undergoing antiretroviral therapy arise increasingly as HIV-1 
infection progresses to AIDS suggesting that HIV-1 is a key contributing 
factor. Previously, our research has shown that the HIV-1 Tat protein 
is such a factor as Tat expression correlates with increased sensitivity 
to SMX-HA, the reactive metabolite of SMX [8,21]. In this study we 
sought to determine the region of the Tat protein mediating this effect. 
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Cell Line 0ng/ml Dox 400ng/ml Dox 1000ng/ml Dox 
Jurkat E6.1 300 n/a n/a
Tat101 264 250 243
Tat101GFP 302 156 265
Tat86GFP 328 310 280
Tat72GFP 262 197 228
Tat48GFP 77 67 106
Tat∆GFP 59 52 57
Pooled Tat48GFP 161 162 137
Pooled Tat∆GFP 149 146 138
Table 1: LC50 values of the various Jurkat T cell lines. All the cells used in the experiments were from clone-specific, stably-transfected cell lines with the exception of the 
two cell lines given the ‘pooled’ moniker. These pooled cell lines were generated by hygromycin B selection post transfection to create a cell line of multiple clones. LC50 
values were calculated using GraphPad Prism v.5 as described in the methods.
 Figure 6: Reactive oxygen species generated in the presence of SMX-HA and the various Tat constructs. After induction with doxycycline, cells from 
the (A) Tat101, (B) Tat101GFP, (C) Tat86GFP, (D) Tat72GFP, (E) Tat48GFP or (F) Tat∆GFP lines were seeded at a concentration of 1×106 cells/ml and 
incubated with 10µM DCFH at 37oC for 1 h. There followed an incubation with different concentrations of SMX-HA for 2 h at which point the fluorescence 
was determined via a plate reader. *P<0.001 vs. 0ng/ml Dox (control cells), #P<0.05 vs. 200ng/ml Dox. Data are mean of three independent experiments.
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Figure 7: Expression of α-tubulin and β-actin in Tat-expressing cells. (A) 
Representative western blots showing protein expression from Cos Tat101GFP 
and Tat72GFP cells. Densitometric analysis of β-actin (B) and α-tubulin (C) 
expression. The Cos 7 cells were induced with doxycycline for 40h and then 
treated with DMSO or 200µM SMX-HA for 2hr at 37oC followed by another 2hr 
incubation with media at 37oC. Protein was extracted, analyzed on SDS-PAGE 
and immunoblotted with anti-α-tubulin, anti-β-actin or anti-BSA antibodies. 
Exogenous BSA was used as a loading control. Data shows average of four 
independent experiments. Lanes 1, 2 and 3 show protein expression from cells 
induced with 0ng/ml, 200ng/ml and 2000ng/ml Dox respectively. Lanes 4, 5 
and 6 show protein expression from cells induced with 0ng/ml, 200ng/ml and 
2000ng/ml Dox respectively, then treated with 200µM SMX-HA. *P<0.05 vs. 
Tat101GFP, +p<0.05 vs. Tat72GFP.
 
Figure 8: Confocal images showing proteins of the cytoskeleton after 
treatment with SMX-HA. Cells from (A) Cos 7, (B) Tat101GFP, (C) Tat72GFP, 
(D) Tat48GFP, and (E) Tat∆GFP-expressing lines were treated with doxycycline 
for 40 h, treated with 200µM SMX-HA for 2 h at 37°C then incubated in media 
for another 2 h. The cells were stained with Hoechst 33258 and then fixed 
with 1% PFA. α-tubulin and β-actin were visualized by immunofluorescence 
staining under a Zeiss LSM 510 META confocal microscope. The scale bar 
represents 20µm.
We also wanted to determine whether the presence of intracellular Tat 
affected tubulin or actin expression levels and adversely affected their 
normal intracellular organization that can result in increased cell death. 
To this end, we engineered deletion mutants of Tat fused to GFP and 
then established stably transfected Jurkat T and Cos7 cell lines.
Initial experiments were conducted to determine the cellular 
distribution of the full-length fusion protein as well as the deletion 
mutants in Cos 7 and Jurkat T cells. As expected, the full-length Tat 
protein, Tat101GFP, and deletion mutants Tat86GFP and Tat72GFP 
localized to the nucleus due to the presence of the previously identified 
nuclear localization sequence/protein transduction domain (NLS/
PTD) [31,32]. In contrast, the Tat48GFP and Tat∆GFP fusion proteins 
were distributed throughout the cell due to the deletion of the NLS/
PTD, which mediates nucleo-cytoplasmic shuttling of Tat. The 
detection of GFP fluorescence in the nucleus of the Tat∆GFP and 
Tat48GFP cells can be attributed to the association of the Tat proteins 
with members of its transcriptional complex such as P-TEFb and PCAF 
(p300/CREB-binding protein Associated Factor) as the key domains 
for such interactions are located within the first 48 amino acids of 
the N-terminus [9,33-35]. The mitochondrial aggregation seen in 
Tat∆GFP-expressing cells may be an indication of an early step towards 
apoptosis. Studies have shown that mitochondrial dynamics have a 
significant role in regulating apoptosis. In particular, Haga et al. [36] 
showed quantitatively via laser scanning cytometry that mitochondrial 
aggregation precedes cytochrome c release during apoptosis and that 
cytochrome c release is dependent on mitochondrial aggregation. We 
have previously shown that TatGFP expression increases cytochrome c 
release into the cytosol of Jurkat pBIG TatGFP cells upon treatment with 
SMX-HA [21]. This suggests that Tat∆GFP expression, in particular, 
primes the cell towards apoptosis more effectively than forms of Tat 
largely restricted to the nucleus, a finding that is consistent with the 
results of the cell viability assays.
The MTT cell viability assays previously demonstrated a significant 
increase in cell toxicity in the presence of increasing concentrations of 
SMX-HA [21]. The differential expression of Tat also had a cooperative 
effect on SMX-HA-mediated toxicity, significantly decreasing cell 
viability further as the expression of the TatGFP protein was increased 
[8]. The failure of Tat72GFP expression in this paper to potentiate 
SMX-HA-mediated cell death is in contrast to previously published 
data [8,21]. This may be due to the fact that the sequence of the 72 
amino acid Tat protein used in the aforementioned publications 
(TatGFP) differs by eleven amino acids from the Tat protein used in 
the current study (Tat72GFP). While both Tat variants may have the 
same inherent transactivating properties it is possible that the amino 
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acid differences in the Tat protein used previously impart a greater 
ability to mediate T cell apoptosis. Peloponese et al. have proposed that 
differences in Tat sequence may affect its ability to transactivate the 
HIV-1 LTR [37]. A similar study carried out by de Mareuil et al. [29] 
showed that Tat variants from patients categorized as rapid progressors 
were significantly more potent in tubulin polymerization and apoptosis 
induction in T cells [29]. Further experiments are needed to more 
clearly define the importance of Tat amino acid sequence variation 
on cell viability and whether different Tat sequence variants confer a 
greater susceptibility to the development of adverse drug reactions. 
The cell death seen via the MTT assays in cells expressing the full-
length Tat proteins (Tat101 and Tat101GFP) may be the result of the 
generation of excess ROS, consistent with a pro-oxidant role for Tat 
[12,38-40]. Experiments designed to directly compare the impact of 
Tat101GFP to Tat101 on cell death, as assessed by the MTT assays, 
demonstrated that the two constructs were not significantly different 
from one another (data not shown). However, none of the deletion 
mutants had the same effect allowing us to conclude that the full-length 
Tat protein is required for the induction of increased ROS in Jurkat 
cells. Though previous reports have shown that Tat deletion mutants 
(Tat72 or Tat86) can induce or augment ROS production in cultured 
cells, this was observed only with the addition of the recombinant 
extracellular Tat protein to the cultures [12,38-40]. Despite its ability 
to induce oxidative stress, expression of the full-length Tat proteins did 
not cause a significant amount of cell death, even after treatment with 
SMX-HA. Indeed the cell lines with lowest cell viability in response 
to SMX-HA treatment (Tat48GFP and Tat∆GFP) did not produce 
significant amounts of ROS. This suggests that ROS and cell death are 
largely unrelated in this context. 
To determine if cell death was due to the effect of Tat expression on 
cytoskeletal proteins, we carried out western blot analysis, which showed 
Tat101GFP was able to significantly down-regulate the expression 
of cytoskeletal proteins β-actin and α-tubulin both before and after 
SMX-HA treatment. This is in agreement with literature showing the 
ability of Tat to down-regulate proteins including those located within 
the cytoplasm [41,42]. The preferential localisation of Tat101GFP to 
the nucleus and its ability to down-regulate the expression of β-actin 
and α-tubulin has the effect of reducing the possibility of interaction 
between the cytoskeletal proteins and Tat101GFP. This in turn ensured 
that apoptosis was not triggered in these cells as shown in the MTT 
viability assays. The differences seen between the Tat101GFP- and 
Tat72GFP-expressing cells in the expression of β-actin and α-tubulin 
further suggests that the C-terminal domain of Tat is necessary for its 
role in the down-regulation of these proteins. 
One possible explanation for the differences in the behaviour 
of Tat protein synthesized internally (intracellular Tat) versus Tat 
protein that enters the cell from the milieu (extracellular Tat) is that 
intracellular Tat localizes predominantly to the nucleus where it carries 
out its transactivating activities, while extracellular Tat appears to 
remain largely in the cytoplasm after being endocytosed where it can 
enhance the stability of polymerized microtubules and subsequently 
induce apoptosis [22,30]. The ability of extracellular Tat to interact 
with tubulin in the cytoplasm of the cell requires the collective integrity 
of amino acids 36-39 as mutation of these four residues to alanine 
was shown to inhibit this interaction [22,29]. Our Tat48GFP and 
TatΔGFP deletion mutants retain amino acids 36-39 and also exhibit 
the greatest reductions in cell viability. Due to the loss of the NLS/
PTD sequence the cytoplasmic concentration of these Tat48GFP and 
TatΔGFP mutants rose, as they were no longer able to exit the cell 
across the plasma membrane. Hence, the levels of these Tat mutants 
in the cytoplasm would be sufficient to bind to tubulin and promote 
the stabilization of polymerized microtubules in a manner similar to 
that seen with extracellular Tat. This in turn leads to a lower threshold 
for apoptosis and higher sensitivity to SMX-HA toxicity. Furthermore, 
the divergent roles of intra- and extracellular Tat illustrates one of the 
ways HIV-1 maintains survival of HIV-1-infected cells while causing 
increased apoptosis of predominantly uninfected bystander cells. Taken 
together these results also re-enforces the importance of Tat nuclear 
sequestration, not only in promoting the transcription of the HIV-
1 provirus, but also in preventing premature cell death before HIV-1 
replication and progeny virus production can be completed. 
The effect of cytoplasmic or extracellular Tat on microtubule 
dynamics and the mitochondrial aggregation that was seen in the 
Tat∆GFP-expressing cells might also be related. Studies have found 
a protein named C19ORF5C to be a dual function microtubule- and 
mitochondria-associated protein that mediates mitotic cell death [43]. 
C19ORF5C is also recruited to chemically-stabilized microtubules 
and accumulates on mitochondria, eventually inducing distinct 
perinuclear aggregation of the mitochondria and resulting in cell 
death [44,45]. The ability of extracellular Tat to bind tubulin and 
stabilize microtubule polymerization leading to apoptosis has been 
well established [22,29,30]. Whether or not Tat-stabilized microtubules 
also recruit C19ORF5C or a similar dual function microtubule- and 
mitochondria-associated protein to induce mitochondrial aggregation, 
and subsequently apoptosis, requires further investigation.
Conclusion
In the general population ADRs are responsible for 3% of all 
hospital admissions and occur in 10-20% of hospital inpatients 
[46]. Additionally, up to 80% of HIV-1-infected patients experience 
an ADR at some point during the course of their treatment thus 
making ADRs a major public health issue due to their frequency and 
potential for increased morbidity and mortality [2,47,48]. SMX is a 
commonly used medication in both HIV-infected and uninfected 
populations and its metabolism is well known, making it an ideal 
model compound. The liver is quantitatively the primary site of SMX 
bioactivation, though metabolism has been shown to occur in other 
organs including the skin, kidney, lung and cells of the immune system 
[49,50]. Furthermore, SMX metabolism by dendritic cells enhances 
their state of activation [51,52]. We have previously shown that SMX-
HA leads to the haptenation of cellular proteins [53] including HIV-
1 infected Jurkat T cells and Jurkat T cells expressing the different 
deletion forms of Tat (data not shown). Additionally, peripheral blood 
leukocytes release cytokines on exposure to SMX-HA that are biased 
to a pro-inflammatory response [54].We show here that when the 
cytoplasmic content of Tat is increased, as exemplified by the Tat∆GFP 
and Tat48GFP constructs in the Jurkat T cell line, this leads to a lower 
threshold for cell death in the presence of SMX-HA. This leads to our 
proposed model of ADRs in HIV-1 patients in which the metabolism of 
SMX leads to the formation of SMX-HA in T cells and other cell types. 
The death of these haptenated cells would lead to the presentation of 
SMX-haptenated antigens, activation of dendritic cells and an immune 
response manifesting clinically as an ADR to SMX. The exact cell death 
pathway involved in the development of a primary immune response to 
SMX still needs to be defined as there is past evidence of both apoptotic 
and necrotic cell death [8,52]. Our data also suggests that in order to 
fully understand the basis of increased ADRs in the HIV-1 population, 
greater attention to HIV-1 Tat sequence variants and their impact on 
disease management may be required. This would be akin to the current 
situation in many jurisdictions where pharmacogenomic screening to 
Citation: Adeyanju K, Dekaban GA, Rieder MJ (2016) Cytoplasmic Distribution of HIV-1 Tat Sensitizes Jurkat T cells to Sulphamethoxazole-
Hydroxylamine Induced Toxicity. HIV Curr Res 1: 105. 
Page  11  of 12
Volume 1 • Issue 1 • 1000105
HIV Curr Res
ISSN: HICR, an open access journal
identify individuals at high-risk for an ADR is recommended before 
the initiation of therapy with certain antiretrovirals [55,56]. Advances 
in our understanding of the mechanisms behind an ADR in HIV-1-
infected individuals will help the development of screening strategies 
that may permit the avoidance of ADRs, the delivery of more effective 
treatment and reduced hospitalizations.
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